JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by thrombotic complications, impacting patient mortality.
• The JAK2V617F mutation is a known independent risk factor for thrombosis in ET.
• Extracellular vesicles (EVs) are emerging as potential biomarkers in myeloproliferative neoplasms and thrombosis.

Purpose of the Study:

• To investigate the relationship between the JAK2V617F mutation and extracellular vesicle (EV) levels in patients with essential thrombocythemia (ET).
• To assess the association between JAK2V617F mutation status and the risk of thrombosis in ET patients.

Main Methods:

• Analysis of 119 ET patients to evaluate circulating extracellular vesicle (EV) levels.
• Statistical analysis to determine the risk of thrombosis associated with the JAK2V617F mutation.
• Comparison of EV levels and procoagulant activity between ET patients and healthy individuals.

Main Results:

• JAK2V617F-positive ET patients showed a significantly increased risk of thrombosis both before diagnosis and during follow-up.
• ET patients exhibited higher levels of platelet-EVs, erythrocyte-EVs, and EVs' procoagulant activity compared to healthy controls.
• Absolute and relative counts of platelet-EVs were significantly elevated in the presence of the JAK2V617F mutation.

Conclusions:

• The JAK2V617F mutation is an independent risk factor for thrombosis in essential thrombocythemia.
• Elevated platelet-EV levels in ET patients with the JAK2V617F mutation suggest a role in thrombosis pathogenesis.
• Findings support the mechanism of JAK2V617F-driven platelet activation contributing to thrombosis in ET.